TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01333267
Drug: PTH (1-34) and PTHrP (1-36)
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
Study: NCT04534439
Drug: APX-115
Normalized name: Apx-115 free base
DrugBank: Isuzinaxib (DB19109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of APX-115 400mg capsule once daily for 12 weeks
Study: NCT03226080
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The neuromuscular blockade group will receive intravenous rocuronium
Study: NCT03226080
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The neuromuscular blockade group will receive intravenous sugammadex for reversal of residual rocuronium
Study: NCT02523313
Drug: Nivolumab + Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) will be applied as IV infusion every 3 weeks for 4 doses. Both study drugs are to be administered on the same day over the first 12 weeks + Nivolumab-Placebo on weeks 3, 5, 9 and 11. After week 12 Nivolumab is given as maintenance and will be applied at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
Study: NCT04439838
Drug: BI 1595043
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1595043
Study: NCT02145741
Drug: Xentuzumab, low dose, every week (qw)
DrugBank: Xentuzumab (DB14871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient to receive low dose of Xentuzumab IV
Study: NCT02145741
Drug: Xentuzumab, middle dose, qw
DrugBank: Xentuzumab (DB14871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient to receive middle dose of Xentuzumab IV
Study: NCT02145741
Drug: Xentuzumab, high dose, qw
DrugBank: Xentuzumab (DB14871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient to receive high dose of Xentuzumab IV
Study: NCT02854137
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.
Study: NCT01361009
Drug: pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: as prescibed by the investigator
Study: NCT02707055
Drug: PF-05190457
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin Receptor Inverse Agonist
Study: NCT01830543
Drug: rivaroxaban 2.5 mg
Normalized name: rivaroxaban 2.5 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One 2.5 mg tablet twice daily for up to twelve months
Study: NCT01830543
Drug: rivaroxaban 15 mg
Normalized name: rivaroxaban 15 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One 15 mg tablet once daily for up to twelve months
Study: NCT01830543
Drug: rivaroxaban 10 mg
Normalized name: rivaroxaban 10 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One 10 mg tablet once daily for up to twelve months
Study: NCT01830543
Drug: aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose aspirin tablet once daily for twelve months
Study: NCT01830543
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One 75 mg tablet once daily for up to twelve months
Study: NCT01830543
Drug: prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One 10 mg tablet once daily for up to twelve months
Study: NCT01830543
Drug: ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 90 mg tablet twice daily for up to twelve months
Study: NCT02728440
Drug: human chorionic gonadotropin, human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug for the treatment of male hypogonadism
Study: NCT03703375
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine
Study: NCT03703375
Drug: Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin
Study: NCT03703375
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine
Study: NCT04433169
Drug: All-trans Retinoic Acid
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA 20 mg, three times a day, for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles
Study: NCT04433169
Drug: VEGFR inhibitor
Normalized name: VEGFR 2 Kinase inhibitor I
DrugBank: VEGFR 2 Kinase inhibitor I (DB17061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGFR inhibitor
Study: NCT03239379
Drug: BNZ132-1-40
Normalized name: BNZ132-1-40
DrugBank: EQ101 (DB17396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable peptide antagonist of IL-2, IL-9 and IL-15
Study: NCT00751530
Drug: raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: New combination ART incorporating raltegravir with other ARVs.
Study: NCT02684019
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: added to propofol sedation
Study: NCT02684019
Drug: Magnesium Sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: added to propofol sedation
Study: NCT00000513
Drug: atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02955134
Drug: Talcid®
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talcid® is allowed to be taken when patients feel stomach pain, acid reflux or heartburn. Continuous taking time should not exceed one week.
Study: NCT02955134
Drug: Compound Azimtamide Entieric-coated Tablets
Normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compound Azimtamide Entieric-coated Tablets are qualified by China Food and Drug Administration. These tablets are allowed to be taken when patients feel fullness, belching or anorexia. Continuous taking time should not exceed one week.
Study: NCT02969317
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination
Study: NCT02969317
Drug: Olodaterol
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed dose combination
Study: NCT01781429
Drug: BVD-523
Normalized name: BVdU
DrugBank: Brivudine (DB03312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
Study: NCT00262080
Drug: ecallantide
Normalized name: Ecallantide
DrugBank: Ecallantide (DB05311)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
Study: NCT02728258
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02273752
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00750555
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg per day orally until disease progression occurs, up to a maximum of 12 months
Study: NCT01111539
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram capsule administered orally, once daily without regard to meals.
Study: NCT01111539
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole capsule administered orally, once daily without regard to meals.
Study: NCT03580382
Drug: Trametinib daily Until PD
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.0 mg daily
Study: NCT03580382
Drug: CDX-3379 (ERBB3 antibody)
Normalized name: CDX
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg/kg IV Q3W
Study: NCT04949906
Drug: Raise serum brain granules
Normalized name: pork brain preparation
DrugBank: Pork (DB10561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Should Yangseronao granules be used in patients undergoing intravenous thrombolysis for the diagnosis of acute ischemic stroke
Study: NCT04949906
Drug: No nourishing serum brain granules are used
Normalized name: pork brain preparation
DrugBank: Pork (DB10561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nourishing serum brain granules are used
Study: NCT01493986
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage. Onset time
Study: NCT04523064
Drug: Empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with diabetes waiting for surgery will receive empagliflozin for at least three months.
Study: NCT02025491
Drug: Liposomal Amphotericin B
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal Amphotericin B will be administered by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment. Complete hemogram, aminotransferases (AST, ALT), blood urea and creatinine will be determined in all patients on days -1, and three times/week up to the end of therapy. Patients will bemonitored for side effects daily. Patients will be followed-up at 1, 2, 3, 4 and 6 months post-therapy. Clinical and laboratory adverse events will be graded according to the Common Toxicity Criteria (CTC) of the National Cancer Institute.
Study: NCT03263936
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose Level #0: 5 mg/m2 Dose Level #1: 7.5 mg/m2 Dose Level #2: 10 mg/m2 Dose Level #3: 15 mg/m2 Dose Level #4: 20 mg/m2 given IV over __ hour on days 1 through 5
Study: NCT03263936
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Age \<18: 180 mg/m2/day once daily PO. Age≥18: 200 mg twice daily PO.
Study: NCT03263936
Drug: Filgrastim (G-CSF)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given on days 5 until evidence of ANC recovery (\>500/µL)5µg/kg/dose IV or SQ (starting at hour 0)
Study: NCT03263936
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2/day IV over 30 minutes (starting at Hour 0 - Immediately after G-CSF)
Study: NCT03263936
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m2/day (Starting at Hour 0.5),IV over 3 hours, days 6-10
Study: NCT01490268
Drug: Sufentanil, Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
Study: NCT01490268
Drug: Sufentanil, Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
Study: NCT01523808
Drug: GRASPA
DrugBank: Red blood cell-encapsulated L-asparaginase (DB17477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
Study: NCT01405846
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250mg od for 6 months
Study: NCT00922194
Drug: Extended Release Metformin
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.5g twice a day to 2g twice a day for at least 12 months or more
Study: NCT00736242
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling
Study: NCT00814372
Drug: MBX-102
Normalized name: MBX-2109
DrugBank: MBX-2109 (DB18658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT00814372
Drug: Actos
Normalized name: Actos
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: over-encapsulated to match MBX-102 and placebo
Study: NCT00814372
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: greater than or equal to 1500 mg/kg day
Study: NCT00869232
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.0mg/m2 days 1, 5, 8, \& 11
Study: NCT00869232
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2 day 3
Study: NCT00869232
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg days 5-8
Study: NCT01540461
Drug: Brivanib
Normalized name: Brivanib
DrugBank: Brivanib (DB11958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity
Study: NCT04664595
Drug: Propofol Fresenius
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: final dose of Propofol (mcg/kg) to reach the target effect-site concentration
Study: NCT04053543
Drug: CXA-10
Normalized name: CXA-10
DrugBank: CXA-10 (DB15026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (10-nitro-9(E)-octadec-9enoic acid)
Study: NCT02179528
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00869232
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg day 5-8
Study: NCT00869232
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2 day 5-8
Study: NCT00869232
Drug: Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2 day 5-8
Study: NCT04361643
Drug: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
Study: NCT00200499
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00433732
Drug: sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00868959
Drug: lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks
Study: NCT00209599
Drug: fospropofol disodium
Normalized name: Fospropofol disodium
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02116660
Drug: Raltegravir (MK-0518)
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir (MK-0518) 400 mg tablets
Study: NCT02116660
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (NVP) 200 mg tablets
Study: NCT02116660
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (3TC) 150 mg tablets
Study: NCT02116660
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir disoproxil fumarate (TDF) 300 mg tablets
Study: NCT02116660
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine (FTC) 200 mg tablets
Study: NCT02116660
Drug: Lopinavir
Normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lopinavir (LPV) 200 mg tablets
Study: NCT02116660
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir (r) 100 mg tablets
Study: NCT02116660
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Atazanavir (ATV) 300 mg tablets
Study: NCT02116660
Drug: Darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir (DAR) 400 mg tablets
Study: NCT00337376
Drug: Rapamune
Normalized name: Rapamune
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
Study: NCT00337376
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
Study: NCT04341675
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.
Study: NCT04474899
Drug: Moxonidine 0.4 MG
Normalized name: moxonidine 0.4 MG
DrugBank: Moxonidine (DB09242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomly assigned to receive moxonidine 0.4mg/daily and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
Study: NCT04474899
Drug: Amlodipine 5mg
Normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomly assigned to receive amlodipine 5mg and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
Study: NCT01718509
Drug: SPD489 (Lisdexamfetamine dimesylate)
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 or 70 mg administered orally, once-daily for up to 12 weeks
Study: NCT03298412
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blinatumomab is administered as a continuous IV infusion.
Study: NCT00264602
Drug: Near Infrared Imaging
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dye injected into or around tumor at the time of surgery
Study: NCT01963299
Drug: 5 ml Ropivacaine 10% + physiological saline
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01963299
Drug: 5 ml Ropivacaine 10% + Clonidine 1 µg/kg
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00869232
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/m2 day 5-8
Study: NCT04070768
Drug: Gemtuzumab Ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab Ozogamicin 3mg/m\^2, Days 1,4,7
Study: NCT04070768
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax, 100,200,400, or 600mg Daily Dose
Study: NCT00489840
Drug: Anecortave Acetate Sterile suspension 15 mg
Normalized name: leuprolide acetate Injectable Suspension
DrugBank: Anecortave acetate (DB05288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months
Study: NCT00489840
Drug: Anecortave Acetate
Normalized name: Anecortave acetate
DrugBank: Anecortave acetate (DB05288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.
Study: NCT02935634
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT02730845
Drug: Intra-articular dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive an intra-articular mixture of 19 ml bupivacaine 0.5% with epinephrine 1:200.000 added to 1ml (1 µg/kg) of dexmedetomidine (total volume 20 ml), and i.v. saline 20 ml infused over 10 min starting with local anesthesia
Study: NCT02730845
Drug: Intravenous dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be injected intra-articularly with mixture of 19 ml 0.5% bupivacaine with epinephrine 1:200.000 and 1 ml of isotonic saline (total volume 20 ml), in addition to i.v. 20 ml saline containing 1 µg/kg dexmedetomidine over 10 min infusion starting with local anesthesia.
Study: NCT00536692
Drug: mecamylamine
Normalized name: Mecamylamine
DrugBank: Mecamylamine (DB00657)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical ocular drops